1. The metabolism of human antithrombin III (ATIll) was studied by using 125 1-labelled tracer.
Introduction
Antithrombin III (ATIII), a natural inhibitor of coagulation, plays a major role in the modulation of haemostasis (Abilgaard, 1967; Yin, Wessler & Stoll, 1971; Harpel & Rosenberg, 1976) . Its importance can be adduced from the increased incidence of deep vein thrombosis in patients with congenital ATIII deficiency (Egeberg, 1965; Filip, Eckstein & Veltkamp, 1976) . In the nephrotic syndrome urinary protein loss resulted in an acquired ATIII deficiency associated with thrombotic episodes (Kauffmann, Veltkamp, Van Tilburg & Van Es, 1978; Jorgensen & Stoffersen, 1979) . In liver dysfunction the pathogenesis for the decrease in ATIll level remains undefined (Abilgaard, Fagerhol & Egeberg, 1970; Chan, Chan, Wong, Tso & Todd, 1979) . Although it has been suggested that ATIll is synthesized by the liver (Koj, Regoeczi, Toews, Leveille & Gareldio, 1978) , immunohistochemical techniques failed to localize ATIII in liver cells (Lee, Chan & Chan, 1979) . The finding of ATIII in the vascular endothelium (Chan & Chan, 1979) and the more recent confirmation of its synthesis by endothelial cells (V. Chan & T. K. Chan, unpublished work) disprove the theory of hepatic cell synthesis. To examine the aetiology of the decreased ATIll levels in chronic liver diseases, we studied ATIll turnover in patients with cirrhosis and carcinoma of liver.
Materials and methods

Subjects
A total of 21 patients with histologically proven chronic liver diseases were studied, of whom seven had cirrhosis due to chronic alcoholism and seven had macronodular cirrhosis with FIG. 1. Elution profile of 125I-label1ed ATIII (specific radioactivity 41· 5 .uCi/50 .ug ) from the heparinSepharose column. The biological1y active tracer was eluted with Tris/HCI buffer containing NaCI (I mol/I).
( Fig. 2) . The radioactive tracer behaved like plasma ATIlI during coagulation by calcium chloride, as evidenced by a second radioactive peak corresponding to the second serum ATIll peak which represents ATIlI-procoagulant complexes (Andersson, Engman & Henningsson, 1977; Chan & Chan, 1979b) (Fig. 2) .
The absence of pyrogens was tested in rabbits for each batch of label according to the British Pharmacopoeia recommendations (British Pharmacopoeia, 1968, Appendix XV H) .
Immunological activity of the 12SI-labelled ATIll was assessed by binding to an excess of monospecific anti-(human ATIll)serum. The specific binding to ATIII antibody was 90%, after correction for non-specific binding, which amounted to 2· 5%. positive hepatitis-B surface antigen (HBsAg) (Lam, Lai, Wu & Todd, 1980) ; six had primary hepatocellular carcinoma (Lai, Lam, Wong, Wu & Todd, 1981) and one had carcinoma of pancreas with secondaries in the liver complicated by superficial thrombophlebitis. All were males, apart from the last patient, and none was receiving oral anticoagulant therapy. Seven healthy male volunteer subjects acted as controls. All subjects gave their informed consent and research was carried out according to the Declaration of Helsinki.
Preparation of radioactive tracer
Highly purified ATIIl (NIBSC 77/618) was 125I-labelled enzymatically by lactoperoxidase as described previously . The 125I-labelled protein was separated from free iodine by gel filtration with Sephadex G-IOO and further purified by affinity chromatography on a heparin/Sepharose column. achieved by mixing for 3 h at room temperature, and the unchanged material removed by washing with deionized water. The gel was further equilibrated with six alternate wash cycles of acetic acid/sodium acetate buffer (0·1 mol/l, pH 4·8) and sodium bicarbonate (0·5 mol/I). The 125 1_ labelled tracer was applied on to the freshly prepared heparin/Sepharose column (l em x 10 cm). Non-heparin-binding tracer was removed by washing with Tris/citrate buffer [Tris/HCI 0·02 mol/I, trisodium citrate 0·01 mol/I (pH 8·5), NaCI 0·15 mol/l] and the heparin-binding 125 1_ labelled ATIll eluted with Tris/HCI buffer (0·02 mol/l, pH 7·8) containing NaCI (l mol/I) (Fig.  I) . These fractions were pooled, sterilized by Millipore filtration (0·045 ,um), and stored in portions at -70°C, in the presence of trace amounts of I% human serum albumin.
Evaluation of I2S I-labelled A TIll tracer in vitro
Crossed immunoelectrophoresis (Laurell, 1965) of a mixture of the purified 125I-labelled ATIll and normal pooled plasma in the presence of heparin (16 units/ml of gel), against anti-(human ATIll)serum and subsequent radioautography showed a single radioactive peak with the same electrophoretic mobility as plasma ATill Fig. 3 shows a representative turnover study in one control subject. The plasma radioactivity was plotted against time and the subsequent curve graphically resolved into three exponential components, with a curve-peeling procedure described previously (Matthews, 1957 ). The metabolic parameters can then be derived mathematically as follows: The test for HBsAg was made in an aliquot of ATIIl (NIBSC 77/618) and it was undetectable by radioimmunoassay.
Analysis based on plasma radioactivity
Turnover studies
To avoid thyroidal uptake of 125 1 each subject received Lugol's solution (20 drops) 1 day before the injection of labelled tracer and daily throughout the course of the study. 1251-labelled ATill (lO,uCi, 3·7 X 10 5 Bq, 12 ,ug) was given intravenously and blood (5 ml) taken into heparinized tubes at 5, 10 and 15 min for the determination of plasma volume. Further sampling was made at 30, 60, 90 and 120 min and at 3, 6, 12 and 24 h, then twice daily for 7 days. In the control and cirrhotic subjects total urine output was collected at 6, 12 and 24 h, then daily for 7 days. Ascitic fluid (2 ml) was removed from one subject with HBsAg-positive cirrhosis and chronic gross ascites at similar time intervals as blood sampling. At the end of the study, the radioactivity of each sample was counted in an Autogamma counter with 80% efficiency for 1251. The amount of non-trichloroacetic acid-precipitable mI was also assessed for all the plasma samples.
patients with carcinoma of liver compensated for their low ATIII, so that the intravascular mass and total body mass of ATIll were normal, whereas, in patients with cirrhosis of liver, the increase in plasma volume (44·91 ± 9·20 ml/kg) was insufficient to compensate for their even lower ATIII levels (13·8 ± 4·4 mg/dl). Thus intravascular mass and total body mass were both significantly decreased (P < 0·001 and <0·0 1 respectively compared with normal values). There was a good correlation between ATIll levels and intravascular mass for all subjects (r = O·8058, P < 0·0001) and for patients with cirrhosis (r = 0·8315, P = 0·0004). The mean fractional catabolic rate (K IO ) was not significantly different in the three groups. However, K IO was found to be positively related to the ATill level in cirrhosis of liver (r = 0·6047, P = 0·0471) but negatively related to the ATIll level in carcinoma of liver (r = -0· 7208, P = 0·0426) (Fig. 4) , and whereas the absolute catabolic rate was normal in the latter, it was decreased in the former group (P < 0·01). The transcapillary rate (KI"J was elevated in the patients, particularly in those with malignancy (5·62 ± 1·81 vs 2·75 ± 1·46 day" in normal subjects).
The patient with secondary carcinoma of liver and thrombophlebitis had normal turnover parameters. Table 2 gives a more detailed analysis of the turnover data in patients with cirrhosis. When they were classified according to the aetiology of their disease, those associated with positive HBsAg had significantly lower values for all the parameters listed, compared with those of patients associated with chronic alcoholism. Similarly, cirrhotic patients with ascites were found to have significantly lower ATIll, and both fractional and absolute catabolic rates lower than those without ascites. Time (days) Analysis based on both plasma and urine radioactivity Fig. 5 illustrates the calculation of 1251-labelled ATill turnover by the clearance method, from both plasma and urine radioactivity measurements (Pearson, VeaH & Vetter, 1958) . If X p = 1251-labeHed ATill in plasma, Xu = 125 1 excreted in urine, then X R , the 1251-labelled ATill retained in the body = 1 -Xu' X E , the fraction of the administered radioactivity in the extravascular space = X R -X p • After equilibrium, in control subjects, the decrease of 1251-labelled ATill from plasma (X p ) and from the extravascular space (X E ) were almost parallel to each other. Whereas, in the cirrhotic patients with mild ascites, the clearance of 1251-labelled ATill from the extravascular space was delayed, as denoted by a slower decline in the radioactivity of the X E x,
curve. This retention of 1251-labelled ATill was even more evident in those patients with gross ascites, when 30-60% of the total injected dose was retained on day 7 (Fig. 6) .
In one patient with gross ascites the radioactivity present in the ascitic fluid varied from 2·35 to 5·99% of the injected dose, which was insufficient to account for the retained X E (50%) on day 7.
The fractional clearance (k c ) can be calculated from daily urine radioactivity (Xu) and mean plasma radioactivity (X p ) after the equilibrium time (te), which for the present study was attained on day 2. For normal subjects and cirrhotic patients without ascites the daily clearance values Time (days) (Xu/Xp) from day 2 to 7 were averaged, such that k c = L (XulXp)/n, where n = number of days. In cirrhotic patients with moderate and gross ascites, in whom there was significant retention of X E radioactivity, the clearance rate (XulXp) from the intravascular compartment was also constant from day 2 to 7 and k c could be similarly derived. Hence it could be concluded that the catabolism of ATIll in these subjects occurred only in the intravascular compartment. Furthermore the fractional catabolic rate (K l o ) derived from the plasma radioactivity analysis was linearly related to the fractional clearance rate (k c ) in the subjects studied and can be represented by (K IO ) = 2·722
Discussion
The 12S1-labelled ATlII used in the present study was found to be similar to plasma ATIll by biological and immunological tests, including heparin-Sepharose affinity chromatography, binding to activated procoagulants on clotting and precipitation by monospecific antiserum. Hence the turnover data obtained with this label can be assumed to reflect that of the total body ATIll pool.
The plasma radioactivity to.~of ATIll was 2·71 ± 0·26 days in normal control subjects, and this was similar in patients with cirrhosis and carcinoma of liver (2·88 ± 0·50 and 2·46 ± 0·38 days respectively). Collen, Schetz, DeCock, Holmer & Verstraete (1977) found similar values in normal subjects and patients with peripheral arterial disease and venous thromboembolism. In addition ATIll turnover was normal in the patient with secondary carcinoma of the liver and active superficial thrombophlebitis, suggesting that the turnover parameters are not grossly disturbed during venous thrombosis. Collen et at. (1977) had shown that these parameters were increased only with heparin treatment.
In patients with cirrhosis of liver ATIll levels were decreased and in many cases lower than that in congenital ATIll deficiency (about 50% normal), yet no clinical evidence of venous thromboembolism was noted, probably because of the low prothrombin and other vitamin K-dependent factors in these patients (Deutsch, 1965) . They tend to be more prone to bleeding from thrombocytopenia and increased fibrinolysis (Kwan, McFadzean & Cook, 1956) . Even though the plasma volume was increased, the intravascular mass and total body mass were still significantly decreased. The decreased absolute catabolic rate indicates decreased production of ATill. These abnormalities of ATIll metabolism were more pronounced in those patients with positive HBsAg and those with ascites. Further insight into the aetiology of low ATIll was obtained when it was shown that the fractional catabolic rate (K 10) was directly related to ATIll level, which means that the low ATIll level was associated with decreased fractional clearance or catabolism. It can be concluded that, in the steady state, the decreased demand for ATIll in cirrhotic patients resulted in a positive feedback on ATIll production and hence low circulating level. However, this very low ATIll could be conducive to acute disseminated intravascular coagulation, which is known to occur in those patients with chronic liver disease progressing to acute liver failure (Verstraete, Vermylen & Collen, 1974) .
Clinically detectable ascites occurred in eight out of 14 cirrhotic patients. In these patients there was a marked retention of 1251-labelled ATIII in the extravascular space. Removal of ascitic fluid at various intervals after injection of the labelled tracer in one patient showed that leakage into the ascitic fluid could not account for the total amount of radioactivity which was retained. Tl.ere appeared another extravascular compartment where the tracer might accumulate. Previous study of albumin exchange between plasma and ascitic fluid had shown that the protein diffused into an adjacent extraperitoneal space other than the peritoneal cavity (Dykes & Jones, 1968) . It seemed that the open twocompartment mamillary system, which explains the metabolism of ATIll in normal subjects adequately (Fig. 7a) , has to be modified for patients with cirrhosis when ascites is present. Analysis by urine clearance (k c ) suggests that catabolism occur only in the intravascular compartment in both normal subjects and cirrhotic patients and thus the calculation of absolute catabolic rate from K 10 values are valid for both groups. For the cirrhotic patients a different compartment system is proposed (Fig. 7b) , where there are two extravascular pools, EV 1 and EV2' in which EV1 equilibrates with EV2 rapidly but the latter (EV~exchanges at a much slower rate with EV1 and the intravascular pool (IV).
In primary carcinoma of liver the ATIll level was moderately decreased, and the increased plasma volume resulted in normalization of the intravascular mass and total body mass in this group. It is of interest to note that the fractional transcapillary ATIll transfer rates were greater in these patients. Contrary to patients with cirrhosis of liver, the absolute catabolic rate was normal, indicating normal ATIll production. However, the fractional catabolic rate (K1o> varied inversely with ATIll level, which would suggest that the low circulating level was associated with increased catabolism. Since it is well known that hepatic malignancy is associated with hypercoagulability (Kwaan, Lo & McFadzean, 1959; Nusbacher, 1964) an increased consumption or catabolism of ATIll may be required to counteract chronic disseminated intravascular coagulation in these patients.
